11.56  -0.08 (-0.69%)		04-18 16:00
Open: 11.69 High: 11.69 Volume: 331,355		Pre. Close: 11.64 Low: 11.26 Market Cap: 711(M)

Short term
Mid term
Targets	6-month :	15.39	1-year :	16.78
Resists	First :	13.18	Second :	14.36
Pivot price	12.87
Supports	First :	11.26	Second :	9.36
MAs	MA(5) :	11.84	MA(20) :	13.11
	MA(100) :	12.17	MA(250) :	10.1
MACD	MACD :	-0.6	Signal :	-0.4
%K %D	K(14,3) :	7.6	D(3) :	6.2
RSI	RSI(14): 21.5
52-week	High :	15.43	Low :	7.07

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.
[ EOLS ] has closed above bottom band by 9.2%. Bollinger Bands are 86.9% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 3 days. This is a sign that the current trend might continue.

If tomorrow:	Open lower	Open higher
High:	11.71 - 11.78	11.78 - 11.85
Low:	11.08 - 11.15	11.15 - 11.23
Close:	11.42 - 11.55	11.55 - 11.69

Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. The company was incorporated in 2012 and is headquartered in Newport Beach, California.

Thu, 18 Apr 2024
When Will Evolus, Inc. (NASDAQ:EOLS) Become Profitable? - Simply Wall St

Tue, 16 Apr 2024
Evolus, Inc. (NASDAQ:EOLS) Sees Significant Decrease in Short Interest - MarketBeat

Tue, 16 Apr 2024
Why Evolus (EOLS) Might Surprise This Earnings Season - Yahoo Movies Canada

Sat, 13 Apr 2024
Vanguard Group Inc. Has $24.67 Million Stock Position in Evolus, Inc. (NASDAQ:EOLS) - Defense World

Sat, 13 Apr 2024
Vanguard Group Inc. Purchases 741,451 Shares of Evolus, Inc. (NASDAQ:EOLS) - MarketBeat

Fri, 12 Apr 2024
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Underperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Outperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Shares Out	62 (M)
Shares Float	39 (M)
Held by Insiders	13 (%)
Held by Institutions	77.1 (%)
Shares Short	4,650 (K)
Shares Short P.Month	4,960 (K)

EPS	-1.09
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	-0.37
Profit Margin	-30.6 %
Operating Margin	-8.4 %
Return on Assets (ttm)	-12.4 %
Return on Equity (ttm)	0 %
Qtrly Rev. Growth	39.7 %
Gross Profit (p.s.)	0
Sales Per Share	3.28
EBITDA (p.s.)	-0.51
Qtrly Earnings Growth	0 %
Operating Cash Flow	-34 (M)
Levered Free Cash Flow	-10 (M)

PE Ratio	-10.71
PEG Ratio	-2.3
Price to Book value	-32.12
Price to Sales	3.51
Price to Cash Flow	-20.91

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.